Skip to main content
    P

    Praxis Precision Medicines Inc (PRAX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $277.62
    +15.03 (+5.72%)

    Market Cap: $7.33B

    Last updated: Nov 06, 2026 at 4:40 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    42%(10/24)
    Avg Surprise
    -9.54%
    Streak
    2 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-3.63
    Range$-5.60 - $-2.74
    19 analysts
    EPS Revisions
    1
    0
    7d
    12
    4
    30d
    EPS Estimate DriftChange to current
    90d ago$-4.03+9.7%
    60d ago$-3.63-0.1%
    30d ago$-3.63-0.1%
    7d ago$-3.62-0.3%
    Current$-3.63
    Revenue Consensus
    $0
    Range$0 - $0
    17 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-3.02
    Range$-8.83 - $-1.07
    19 analysts
    Revenue Consensus
    $830710
    Range$0 - $7M
    19 analysts
    Last 12 of 25 reported quarters and 2 upcoming estimates
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Dec 26EST
    		-$-3.02$-8.83 - $-1.07--19--
    Sep 26EST
    		-$-3.63$-5.60 - $-2.74--19
    12
    4
    30d
    		-
    Jun 26
    Reported Aug 6
    		$-2.87$-3.60$-5.33 - $-3.04+20.28%Beat16
    No revisions (30d)
    		+13.3%
    Mar 26
    Reported May 7
    		$-3.20$-3.68$-5.23 - $-2.98+13.04%Beat12
    1
    4
    30d
    		+2.7%
    Dec 25
    Reported Feb 19
    		$-3.50$-3.13$-4.16 - $-2.17-11.82%Miss14
    1
    1
    30d
    		-19.0%
    Sep 25
    Reported Nov 5
    		$-3.36$-3.45$-4.06 - $-3.10+2.61%Beat12
    0
    1
    30d
    		-22.2%
    Jun 25
    Reported Aug 4
    		$-3.31$-3.36$-3.96 - $-2.93+1.49%Beat10
    0
    1
    30d
    		-90.2%
    Mar 25
    Reported May 2
    		$-3.29$-3.21$-3.69 - $-2.77-2.49%Miss9
    1
    6
    30d
    		-15.8%
    Dec 24
    Reported Feb 28
    		$-2.94$-2.82$-3.23 - $-2.41-4.29%Miss9
    0
    2
    30d
    		+1.0%
    Sep 24
    Reported Nov 6
    		$-2.75$-1.95$-2.23 - $-1.74-41.03%Miss10
    No revisions (30d)
    		-1.9%
    Jun 24
    Reported Aug 13
    		$-1.74$-2.32$-3.24 - $-1.72+25.00%Beat10
    No revisions (30d)
    		+76.3%
    Mar 24
    Reported May 13
    		$-2.84$-2.16$-2.24 - $-1.72-31.48%Miss7
    No revisions (30d)
    		+73.3%
    Dec 23
    Reported Mar 5
    		$-2.97$-3.18$-3.59 - $-2.99+6.60%Beat6
    1
    0
    30d
    		+77.2%
    Sep 23
    Reported Nov 7
    		$-2.70$-4.89$-5.06 - $-4.81+44.79%Beat6
    1
    0
    30d
    		+81.2%

    Key Metrics

    Valuation
    P/E Ratio-21.47EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-38.90%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio15.73xQuick Ratio15.73x
    Trading Statistics
    Beta2.84Avg Volume485.18K
    52-Week High$392.7052-Week Low$160.11

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$277.45
    SMA 20$264.56
    SMA 50$291.73
    SMA 200$313.95
    EMA 10$274.37
    EMA 20$273.73
    EMA 50$287.47
    EMA 200$285.35

    MACD

    Line: -2.12Signal: -5.31Hist: 3.20

    ADX

    ADX: 18.4+DI: 16.4-DI: 21.2

    Aroon & PSAR

    Aroon Up4.0
    Aroon Down32.0
    PSAR$294.28

    Bollinger Bands

    Upper Band$296.12
    Lower Band$233.00
    %B Position2386%(Upper)
    Band Width0.71

    RSI (14-Day)

    Neutral
    50.6

    Momentum Oscillators

    Stoch %K59.3
    Stoch %D65.2
    Williams %R-39.3
    ROC (10d)9.7%
    Momentum24.66
    CCI (20d)41.4
    MFI (14d)61.3

    Volatility Measures

    ATR (14d)$14.44(5.2%)
    StdDev (20d)15.78
    Hist Vol64.8%(High)

    Volume Flow

    VWAP$272.50
    OBV23.7M
    AD Line-15.7M
    CMF (20d)-0.091

    Volume Metrics

    Avg Vol (20d)474.1K
    Vol Ratio0.6x
    VWMA (20d)$261.03

    Pivot Points

    R3$298.98
    R2$291.26
    R1$276.93
    Pivot Point$269.21
    S1$254.88
    S2$247.16
    S3$232.83

    Advanced Oscillators

    TSI-4.16
    Ultimate Osc46.5
    KST-30.57

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$7.46M$302,000$357,000$431,000$515,000$468,000
    Cost of Revenue$0$0$28,000$0$0$0$56.29M$0$0$0$18.39M$0
    Gross Profit$0$0$-28,000$0$0$0$7.46M$302,000$357,000$431,000$515,000$468,000
    Operating Expenses$96.90M$105.86M$97.04M$78.36M$76.07M$74.73M$71.42M$57.14M$37.84M$42.32M$28.32M$25.98M
    R&D$69.42M$77.99M$77.51M$65.80M$63.01M$60.81M$56.29M$41.88M$27.26M$26.98M$18.39M$17.26M
    SG&A$27.49M$27.87M$19.54M$12.56M$13.06M$13.92M$15.13M$15.26M$10.59M$15.33M$9.93M$8.72M
    Operating Income$-96,904,000$-105,860,000$-97,044,000$-78,359,000$-76,067,000$-74,728,000$-63,956,000$-56,835,000$-37,488,000$-41,886,000$-27,806,000$-25,516,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-83,720,000$-92,561,000$-88,911,000$-73,934,000$-71,127,000$-69,296,000$-58,679,000$-51,910,000$-32,677,000$-39,553,000$-26,878,000$-24,632,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-83,720,000$-92,561,000$-88,911,000$-73,934,000$-71,127,000$-69,296,000$-58,679,000$-51,910,000$-32,677,000$-39,553,000$-26,878,000$-24,632,000
    EBITDA$-84,376,000$-93,177,000$-89,554,000$-74,620,000$-72,068,000$-70,478,000$-60,022,000$-53,823,000$-34,101,000$-39,525,000$-26,767,000$-24,523,000
    EBIT$-83,720,000$-92,561,000$-88,911,000$-73,934,000$-71,127,000$-69,296,000$-58,679,000$-51,910,000$-32,677,000$-39,553,000$-26,878,000$-24,632,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PRAX

    News

    Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Praxis Precision Medicines, Inc. (Nasdaq: PRAX) announced that its Compensation Committee granted restricted stock unit awards covering 23,219 shares of common stock to 59 new non-executive employees on November 2...

    Stock Titan•11/5/26•Somewhat-Bearish

    No sole voting power is reported by Abigail P. Johnson for her Praxis Precision Medicines (PRAX) stake.

    FMR LLC and Abigail P. Johnson have each reported beneficial ownership of 2,565,828.27 shares, or 9.2%, of Praxis Precision Medicines (PRAX) common stock. While FMR LLC holds sole voting power over most of its shares...

    Stock Titan•11/5/26•Neutral

    Praxis Precision Medicines stock gets 23,219-share hiring grant

    Praxis Precision Medicines announced an equity grant of 23,219 restricted stock units to 59 new non-executive employees on November 2, 2026. These awards are part of the company's 2024 Inducement Plan...

    ad-hoc-news.de•11/4/26•Somewhat-Bullish

    (PRAX) Movement Within Algorithmic Entry Frameworks

    Praxis Precision Medicines Inc. (NASDAQ: PRAX) shows near-term neutral sentiment but mid and long-term strength...

    Stock Traders Daily•11/4/26•Somewhat-Bullish

    Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Praxis Precision Medicines, Inc. announced that its Compensation Committee granted restricted stock unit awards covering an aggregate of 23,219 shares of common stock to fifty-nine new non-executive employees on November...

    Yahoo Finance•11/4/26•Somewhat-Bullish

    PRAX Valuation and Fair Value

    P/E
    -21.5x
    P/B
    6.0x
    See GNG's fair value

    PRAX Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -38.9%

    PRAX Competitors

    CompanyTicker
    Caris Life Sciences, Inc. Common StockCAI
    Axsome Therapeutics IncAXSM
    Abivax SA American Depositary SharesABVX
    Kiniksa Pharmaceuticals LtdKNSA
    10X Genomics IncTXG
    Merus BVMRUS
    Rhythm Pharmaceuticals IncRYTM
    Amneal Pharmaceuticals, Inc. Class A Common StockAMRX

    Sector: Healthcare

    PRAX Analyst Ratings

    Consensus
    Buy
    Analysts
    19
    Strong Buy
    3
    Buy
    14
    Hold
    1
    Sell
    1
    Strong Sell
    0

    PRAX Bull Case vs Bear Case

    Bull case

    • PRAX grew quarterly revenue 1349.0% year over year.
    • 89.5% of PRAX's analyst ratings are Buy or Strong Buy.

    PRAX Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    -2.8%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-3.63
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    12 up, 4 down

    PRAX Earnings Date

    PRAX reports Nov 9, 2026, before the open. The date is confirmed.

    PRAX Earnings Call

    The latest PRAX earnings call transcript on file is labeled 2026Q2.

    Read the 2026Q2 transcript

    PRAX ETF Holders

    GNG tracks 14 ETFs that hold PRAX. The largest weights:

    1. abrdn Healthcare Investors (HQH), 1.81% of the fund
    2. State Street SPDR S&P Biotech ETF (XBI), 1.19% of the fund
    3. iShares Biotechnology ETF (IBB), 0.49% of the fund
    4. Fidelity Enhanced Small Cap Core ETF (FESM), 0.27% of the fund
    5. Vanguard Morningstar Small-Cap Value ETF (VBR), 0.17% of the fund
    Open the ETF Stock Exposure tool for PRAX

    See insider activity

    Frequently Asked Questions About PRAX

    When does PRAX report earnings?

    Praxis Precision Medicines Inc (PRAX) is confirmed to report earnings on Nov 9, 2026.

    Does PRAX pay dividends?

    Praxis Precision Medicines Inc (PRAX) does not currently pay a regular dividend.

    What is PRAX's market cap?

    Praxis Precision Medicines Inc (PRAX) has a market capitalization of $7.33B with a current stock price of $277.62.

    Related stocks

    Sector: Healthcare

    All stocks starting with P

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In